Latex immunoturbidimetry detection kit for IgG4
By designing an IgG4 assay kit containing a specific composition, using a kit composed of MES buffer and glycine buffer, combined with an anti-IgG4 antibody fragment with a lack of Fc, the sensitivity and accuracy of IgG4 detection in the prior art was solved. , achieves detection effects of high sensitivity, accuracy and anti-interference ability, and is suitable for clinical applications.
Patent Information
- Application Number
- CN202411230264.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-03
- Publication Date
- 2024-12-03
AI Technical Summary
In the prior art, the detection of IgG4 has problems related to sensitivity, accuracy and linearity, and it is difficult to achieve a detection method with high sensitivity, good accuracy, strong anti-interference ability and low cost.
Provided is an IgG4 assay kit, comprising a first reagent and a second reagent, the first reagent consisting of MES buffer, a dispersant, a polymerization agent, a surfactant and a preservative, and the second reagent is composed of glycine buffer, anti-IgG4 The antibody-coated latex microspheres, sucrose, fish skin gelatin and preservatives are composed of anti-IgG4 antibody fragments (such as Fab') that lack Fc to improve the specificity and accuracy of the assay.
It realizes IgG4 detection with high sensitivity, good accuracy, strong anti-interference ability and low cost, meets the linear range and repetition requirements of clinical applications, and shows strong stability and anti-HAMA interference performance.
Smart Images

Figure BDA0005026613860000051 
Figure BDA0005026613860000061 
Figure BDA0005026613860000071
Abstract
Description
Technical Field
[0001] The present invention relates to the fields of medicine, immunity and in vitro diagnosis, and in particular to a kit for detecting IgG4 by immunoturbidimetry. Background Art
[0002] In the human body, there are five types of immunoglobulins, namely IgG, IgA, IgM, IgD and IgE. In the body fluids and blood that infiltrate tissues and cells, most antibodies are IgG. IgG itself has four subtypes, namely IgG1, IgG2, IgG3, and IgG4.
[0003] Different IgG subtypes correspond to different antigenic properties. The differences between IgG subtypes can be reflected in different biologically important functions, such as antigen recognition, complement activation, and cell surface receptor binding. Many studies have shown that the concentration of serum IgG subtypes is associated with deviations from the reference interval and different disease states.
[0004] In the blood, different IgG subtypes exist in different proportions, with IgG1 accounting for 60%-70%, IgG2 accounting for 20%-30%, IgG3 accounting for 5-8%, and IgG4 accounting for only 1-3%. In addition, the presence of different IgG subtypes is also related to age. For example, when the human body is 5-7 years old, IgG1 and IgG3 can rise to adult levels, while IgG2 and IgG4 levels increase slowly (they can rise to adult levels after 10 years old).
[0005] IgG4-related disease (IgG4-RD) is a group of diseases newly discovered in recent years. In 2010, it was uniformly named IgG4-RD. Its clinical characteristics are manifested as elevated serum IgG4 levels; imaging findings of localized or diffuse enlargement, nodules, masses, and wall thickening of one or more organs; infiltration of lymphocytes and IgG4+ plasma cells in the affected tissues, accompanied by fibrotic and sclerotic changes.
[0006] Elevated IgG4 levels are seen in autoimmune diseases (such as systemic lupus erythematosus, autoimmune pancreatitis (AIP)), chronic bacterial infections (such as tuberculosis, chronic bronchitis), and immune proliferative diseases (such as multiple myeloma).
[0007] Decreased IgG4 is seen in cases of massive protein loss (such as nephrotic syndrome), lymphoreticular system tumors (such as lymphosarcoma, Hodgkin's disease), and immunodeficiency diseases (such as loss of immune protein heavy chains).
[0008] In the prior art, the detection of IgG4 includes scattering immunoturbidimetric platform (special protein analyzer), magnetic particle chemiluminescence method, latex immunoturbidimetric method, fluorescent immunochromatography method, and enzyme-linked immunosorbent assay. The prior art has problems with sensitivity, accuracy, and linearity.
[0009] In view of this, there is still a need in the art for an IgG4 detection reagent with high sensitivity, good accuracy, strong anti-interference ability, low cost and stability. Summary of the invention
[0010] In view of the aforementioned needs in the art, some embodiments of the present disclosure provide an IgG4 assay kit comprising a first reagent, a second reagent, and an optional calibrator.
[0011] In some embodiments, the first reagent of the present disclosure comprises:
[0012] 10mM to 200mM MES buffer,
[0013] 0.05M to 1M dispersant,
[0014] 0.1% to 2.5% w / v polymerization promoter,
[0015] 0.05% to 1.0% w / v surfactant,
[0016] 0.05% to 2% w / v preservatives,
[0017] pH 5 to 8, preferably 6.5.
[0018] In some embodiments, the second reagent of the present disclosure comprises:
[0019] 10mM to 200mM glycine buffer,
[0020] 0.2% w / v anti-IgG4 antibody-coated latex microspheres,
[0021] 0.05 to 0.50 g / L anti-IgG4 antibody,
[0022] 1% to 10% w / v sucrose,
[0023] 0.2% to 5% w / v fish skin gelatin,
[0024] 0.05% to 0.5% w / v preservatives,
[0025] The pH is 7 to 8, preferably 7.5.
[0026] In some embodiments, the dispersant is selected from the group consisting of sodium chloride, potassium chloride, potassium thiocyanate, preferably sodium chloride.
[0027] In some embodiments, the aggregation promoter is selected from: PEG4000, PEG6000, PEG8000, PEG12000, preferably PEG6000.
[0028] In some embodiments, the surfactant is selected from the group consisting of: TW20, TW80, Emulgen A90, Thesit, Brijil23, preferably Emulgen A90.
[0029] In some embodiments, the preservative is selected from: PC300, NaN3, PC950, BND, preferably NaN3.
[0030] In some embodiments, the average particle size 50 nm of the latex microspheres is 250 nm, preferably 100 nm.
[0031] In some embodiments, the anti-IgG4 antibody in the IgG4 assay kit of the present disclosure is an anti-IgG4 antibody fragment lacking Fc. The anti-IgG4 antibody fragment lacking Fc is selected from the group consisting of: Fab, Fab', (Fab')2 and Fv.
[0032] In some specific embodiments, the Fc-deficient anti-IgG4 antibody fragment is (Fab')2.
[0033] In some specific embodiments, the IgG4 assay kit of the present disclosure comprises:
[0034] The first reagent comprises or consists of the following:
[0035] 100mM MES buffer,
[0036] 500mM NaCl,
[0037] 2.20% w / v PEG6000,
[0038] 0.50%w / v Emulgen A90,
[0039] 0.20% w / v NaN3,
[0040] pH 6.5;
[0041] The second reagent comprises or consists of:
[0042] 100mM glycine buffer,
[0043] 0.20% w / v polystyrene latex particles coated with anti-IgG4 antibody fragment (Fab')2, 0.10 g / L anti-IgG4 antibody fragment (Fab')2,
[0044] 8% w / v sucrose,
[0045] 2.0% w / v fish skin gelatin,
[0046] 0.20% w / v NaN3,
[0047] pH 8.0;
[0048] The average particle size of the polystyrene latex particles is 100 nm. BRIEF DESCRIPTION OF THE DRAWINGS
[0049] Figure 1 .Correlation between the reagents of this application and the measured values of Siemens reagents. DETAILED DESCRIPTION
[0050] Example 1. Preparation of the kit of this application
[0051] 1. The first reagent contains:
[0052] 100mM MES buffer,
[0053] 500mM NaCl,
[0054] 2.20% PEG6000
[0055] 0.50% A90,
[0056] 0.20% NaN3,
[0057] 10 M NaOH to adjust pH to 6.5;
[0058] At room temperature, the first reagent was prepared as described above (% represents g / 100 ml, i.e. w / v).
[0059] 2. Preparation process of the second reagent
[0060] 1) Add 0.5 ml of a polystyrene latex solution (concentration 10%) with an average particle size of 100 nm to 5.0 ml of 0.05 M MES (pH 5.5) and 150 μl of EDC (carbodiimide, concentration 5 mg / mL), and let stand at 37°C for 1 hour;
[0061] 2) The monoclonal antibody with the Fc end removed by enzyme cleavage was diluted with 10 ml of 0.05 M Hepes buffer (pH 7.0) and immediately added to the buffer in step 1) and reacted at 37° C. for 2 hours;
[0062] 3) Add 1 ml of 0.1 M glycine buffer (pH 7.5) and stir for 1 hour to terminate the reaction;
[0063] 4) Wash with 20 ml of 100 mM glycine buffer (pH 7.5), centrifuge and remove the supernatant, and wash three times;
[0064] 5) resuspending the latex particles with a storage buffer to disperse them into a white latex suspension;
[0065] 3. The second reagent contains:
[0066] 0.20% IgG4 monoclonal antibody-coated polystyrene latex particles,
[0067] The concentration of IgG4 monoclonal antibody on the particles in the second reagent is relative to 0.10g / L,
[0068] 100mM glycine buffer,
[0069] 8% sucrose,
[0070] 2.0% fish skin gelatin,
[0071] 0.20%NaN3,
[0072] pH8.0.
[0073] Optimization Example 1. Antibody Selection
[0074] The kit was prepared according to the method of Example 1, and the antibodies were replaced with antibodies of different types to observe the effects on the correlation and specificity of the measured values. The experimental data are as follows:
[0075] Table 1
[0076]
[0077] The specific information of Antibody 1 to Antibody 4 is as follows:
[0078] Table 2
[0079] Antibody factory Part Number Antibody 1 Merck ABIGG4-W10 Antibody 2 Beijing Aibosheng K06087M0 4D03C Antibody 3 Anbijin MAB1312 Antibody 4 Beijing Aibosheng K06216M0 3D08C
[0080] As can be seen from the above table, antibody 1 has a good correlation with the control reagent, but the cross-reaction rate with IgG1 is relatively high; antibody 2 has a poor correlation with the control reagent; antibody 3 has a correlation with the control reagent, but the correlation coefficient is only about 0.76; antibody 4 has a good correlation with the control reagent and has no cross-reaction with IgG1, IgG2, and IgG3, but there is a certain HAMA interference.
[0081] After the Fc end of antibody 4 was removed, the correlation with the measured value of the control reagent was not affected, and there was no cross-reaction with IgG1, IgG2, and IgG3. The detection results of HAMA samples were greatly improved. That is, when the IgG4 monoclonal antibody with the Fc end removed was used, the detection accuracy and specificity were significantly improved.
[0082] Optimization Example 2. Optimization of Stabilizer
[0083] The kit was prepared according to the method of Example 1, except that different stabilizers were included and grouped as follows:
[0084] -Control group:
[0085] The first reagent is the same as the first reagent in Example 1;
[0086] The second reagent does not contain a protein stabilizer (such as 2% fish skin gelatin), and the rest is the same as the second reagent in Example 1.
[0087] - Group 1:
[0088] The first reagent is the same as the first reagent in Example 1;
[0089] Second reagent: Compared with the second reagent of Example 1, 2.0% fish skin gelatin was replaced with 2.0% BSA.
[0090] - Group 2:
[0091] The first reagent is the same as the first reagent in Example 1;
[0092] Second reagent: Compared with the second reagent of Example 1, 2.0% fish skin gelatin was replaced with 2.0% casein.
[0093] - Group 3:
[0094] The first reagent is the same as the first reagent in Example 1;
[0095] Second reagent: Compared with the second reagent of Example 1, 2.0% fish skin gelatin was replaced with 0.5% PA1080.
[0096] - Group 4:
[0097] That is, the reagent of the present application in Example 1
[0098] Table 3
[0099]
[0100]
[0101] Table 4
[0102]
[0103] From the above data, it can be seen that the use of fish skin gelatin in the second reagent can not only improve the sensitivity of the reagent, reduce the blank, and increase the reaction absorbance, but also optimize the stability of the reagent.
[0104] Test Example 1. Comparison with commercially available reagents
[0105] The kit was prepared according to the method of Example 1, and the serum samples were tested, and then compared with the measured values of the prior art kit (Siemens latex reagent). The results are as follows.
[0106] Table 5
[0107]
[0108]
[0109] It can be seen from the above table that the reagent of the present application has a good correlation with the measured values of the Siemens reagent.
[0110] Test Example 2. Linear Range
[0111] The kit was prepared according to the method of Example 1, and 4.0 g / L high-value serum was tested. The high-value serum was diluted with purified water according to the arithmetic dilution method, and the linearity of the kit was tested.
[0112] Table 6. Kit linearity
[0113]
[0114]
[0115] It can be seen that the kit of the present application can achieve a linear detection range of 4.0 g / L, and about 96% of routine clinical samples have IgG4 concentrations below 2.0 g / L, which meets clinical application requirements.
[0116] Test Example 3. Repeatability
[0117] The kit was prepared according to the method of Example 1, and 3 samples with different concentrations were selected. Each sample was tested 10 times continuously, and the repeatability precision of the test was calculated.
[0118] Table 7. Precision test
[0119] Serial number Sample 1 Sample 2 Sample 3 Sample 4 Sample 5 1 0.38 0.33 0.22 0.10 0.07 2 0.39 0.31 0.22 0.10 0.07 3 0.40 0.32 0.23 0.11 0.08 4 0.40 0.31 0.22 0.12 0.08 5 0.39 0.32 0.22 0.11 0.08 6 0.41 0.32 0.21 0.11 0.07 7 0.39 0.32 0.23 0.12 0.08 8 0.40 0.31 0.23 0.10 0.08 9 0.39 0.32 0.23 0.10 0.08 10 0.41 0.32 0.22 0.11 0.07 Mean 0.40 0.32 0.22 0.11 0.08 SD 0.01 0.01 0.01 0.01 0.01 CV 2.4% 2.0% 3.0% 7.3% 6.8%
[0120] It can be seen that the kit has good detection repeatability. The reference range of IgG4 is 2.0g / L. The kit has good repeatability within the reference range and meets the clinical application requirements.
[0121] Test Example 4. Reagent Stability
[0122] The reagent kit was prepared according to the method of Example 1. Some of the reagents were put into a 37°C incubator for accelerated storage for 7 days. Then, some of the reagents were taken out and calibrated on a machine together with the 4°C reagents. Samples were tested to observe the accelerated stability of the reagents.
[0123] Table 8. Changes in absorbance after acceleration
[0124]
[0125]
[0126] Table 9. Changes in the measured values of the kit after acceleration
[0127] Serum samples 4 degrees 37 degrees for 3 days change 1 0.16 0.18 0.02 2 0.36 0.36 0.00 3 0.14 0.15 0.01 4 0.05 0.06 0.01 5 0.23 0.25 0.02 6 0.49 0.48 -0.01 7 0.48 0.49 0.01 8 0.92 0.88 -0.04 9 0.55 0.55 0.00 10 0.58 0.57 -0.01 11 0.57 0.56 -0.01 12 0.59 0.57 -0.02 13 0.46 0.46 0.00 14 0.66 0.64 -0.02 15 0.61 0.59 -0.02 16 1.12 1.05 -0.07 17 1.70 1.64 -0.06 18 1.73 1.69 -0.04 19 4.21 4.13 -0.08 20 2.72 2.61 -4%
[0128] It can be seen from the data in Tables 8 and 9 that the change in the calibrated absorbance of the reagent after 7 days of acceleration is within 5%, the deviation of low-value samples is within 0.2 g / L, and the relative deviation of high-value samples is within 5%. The reagent is relatively stable and meets the requirements for clinical use.
[0129] Test Example 5. Anti-interference
[0130] Table 10
[0131]
[0132]
[0133] It can be seen from the above table that adding different concentrations of bilirubin, fat emulsion, rheumatoid factor and human hemoglobin interfering substances has no obvious effect on the measured value of the reagent, and the measured value deviation is within 5%. For the rheumatoid factor of 227IU / ml, the measured value deviation is within 10%.
[0134] Table 11
[0135] HAMA samples Siemens measurement This application kit measured value 1 1.00 0.99 2 0.15 0.14 3 0.43 0.42 4 0.81 0.79 5 0.27 0.25
[0136] As can be seen from the table above, the test results of the commercialized HAMA samples (commercially available interference samples, including human anti-mouse antibodies) of the reagents of the present application and the Siemens reagents are close, and the HAMA sample test results are all negative, showing strong anti-HAMA interference performance.
[0137] Table 12
[0138]
[0139]
[0140] As can be seen from the above table, when commercial high-concentration IgG1, IgG2, and IgG3 antigen subtypes were used as test samples to detect the IgG4 concentration, the test results were only near the blank limit, and the calculated cross-reaction rates were all within 1.5%, with no cross-reaction, indicating good specificity.
[0141] Siemens reagent is a scattering reagent. The advantage of scattering is that it can improve sensitivity, but the linear range of detection is narrow, so when using Siemens, the sample needs to be diluted 2000 times. However, the reagent of Example 1 of the present application has a wider range of application and can be applied to various transmission biochemical analyzer platforms without diluting the sample.
Claims
1. An IgG4 assay kit, comprising: First reagent, The second reagent, and Optionally, calibrators; in, The first reagent comprises: 10mM to 200mM MES buffer, 0.05M to 1M dispersant, 0.1% to 2.5% w / v polymerization promoter, 0.05% to 1.0% w / v surfactant, 0.05% to 2% w / v preservatives, pH 5 to 8, preferably 6.5; Wherein, the second reagent comprises: 10mM to 200mM glycine buffer, 0.2% w / v anti-IgG4 antibody-coated latex microspheres, 0.05 to 0.50 g / L anti-IgG4 antibody, 1% to 10% w / v sucrose, 0.2% to 5% w / v fish skin gelatin, 0.05% to 0.5% w / v preservatives, pH 7 to 8, preferably 7.5; The dispersant is selected from: sodium chloride, potassium chloride, potassium thiocyanate, preferably sodium chloride; The polymerization promoter is selected from: PEG4000, PEG6000, PEG8000, PEG12000, preferably PEG6000; The surfactant is selected from: TW20, TW80, Emulgen A90, Thesit, Brijil23, preferably Emulgen A90; The preservative is selected from: PC300, NaN3, PC950, BND, preferably NaN3; The average particle size 50 nm of the latex microspheres is 250 nm, preferably 100 nm.
2. The IgG4 assay kit according to claim 1, in: The anti-IgG4 antibody is an anti-IgG4 antibody fragment lacking Fc; Preferably, the Fc-deficient anti-IgG4 antibody fragment is selected from the group consisting of: Fab, Fab', (Fab')2, and Fv.
3. The IgG4 assay kit according to claim 1, in: The first reagent comprises: 100mM MES buffer, 500mM NaCl, 2.20% w / v PEG6000, 0.50%w / v Emulgen A90, 0.20% w / v NaN3, pH 6.5; The second reagent comprises: 100mM glycine buffer, 0.20% w / v polystyrene latex particles coated with anti-IgG4 antibody fragment lacking Fc, 0.10 g / L anti-IgG4 antibody fragment lacking Fc, 8% w / v sucrose, 2.0% w / v fish skin gelatin, 0.20% w / v NaN3, pH 8.0; The average particle size of the polystyrene latex particles is 100 nm; The anti-IgG4 antibody fragment lacking Fc (Fab')2.
